Handelsbanken Fonder AB Has $245,000 Stock Position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)

Handelsbanken Fonder AB raised its stake in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) by 24.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 59,455 shares of the biotechnology company’s stock after buying an additional 11,600 shares during the period. Handelsbanken Fonder AB’s holdings in Ironwood Pharmaceuticals were worth $245,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in IRWD. PNC Financial Services Group Inc. grew its holdings in Ironwood Pharmaceuticals by 152.2% in the fourth quarter. PNC Financial Services Group Inc. now owns 4,383 shares of the biotechnology company’s stock worth $50,000 after purchasing an additional 2,645 shares during the period. CWM LLC increased its position in shares of Ironwood Pharmaceuticals by 55.1% during the 2nd quarter. CWM LLC now owns 6,600 shares of the biotechnology company’s stock valued at $43,000 after purchasing an additional 2,345 shares during the last quarter. SG Americas Securities LLC bought a new stake in shares of Ironwood Pharmaceuticals during the 1st quarter worth $91,000. GAMMA Investing LLC boosted its holdings in shares of Ironwood Pharmaceuticals by 344.1% in the 2nd quarter. GAMMA Investing LLC now owns 10,526 shares of the biotechnology company’s stock worth $69,000 after buying an additional 8,156 shares during the last quarter. Finally, EntryPoint Capital LLC boosted its holdings in shares of Ironwood Pharmaceuticals by 517.4% in the 1st quarter. EntryPoint Capital LLC now owns 10,589 shares of the biotechnology company’s stock worth $92,000 after buying an additional 8,874 shares during the last quarter.

Insider Activity

In other news, insider Minardo John sold 9,910 shares of the business’s stock in a transaction on Monday, August 12th. The stock was sold at an average price of $4.27, for a total value of $42,315.70. Following the completion of the transaction, the insider now owns 284,661 shares in the company, valued at $1,215,502.47. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 12.90% of the company’s stock.

Analysts Set New Price Targets

IRWD has been the subject of several research reports. Capital One Financial downgraded Ironwood Pharmaceuticals from an “overweight” rating to an “equal weight” rating and cut their price target for the stock from $12.00 to $4.00 in a research note on Thursday, August 8th. Leerink Partners initiated coverage on Ironwood Pharmaceuticals in a report on Monday, September 9th. They set a “market perform” rating and a $5.00 price objective on the stock. StockNews.com upgraded shares of Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, July 16th. Wells Fargo & Company lowered their price objective on Ironwood Pharmaceuticals from $14.00 to $12.00 and set an “overweight” rating for the company in a research report on Friday, August 9th. Finally, Leerink Partnrs raised shares of Ironwood Pharmaceuticals to a “hold” rating in a research note on Monday, September 9th. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $12.17.

Ironwood Pharmaceuticals Stock Up 0.7 %

NASDAQ IRWD opened at $4.29 on Tuesday. The stock’s 50 day moving average is $4.51 and its 200 day moving average is $6.08. The firm has a market capitalization of $671.51 million, a PE ratio of -0.63 and a beta of 0.48. Ironwood Pharmaceuticals, Inc. has a twelve month low of $3.79 and a twelve month high of $15.70.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.